KR20230003410A - L-4-클로로키뉴레닌의 투여형 및 치료적 용도 - Google Patents
L-4-클로로키뉴레닌의 투여형 및 치료적 용도 Download PDFInfo
- Publication number
- KR20230003410A KR20230003410A KR1020227044517A KR20227044517A KR20230003410A KR 20230003410 A KR20230003410 A KR 20230003410A KR 1020227044517 A KR1020227044517 A KR 1020227044517A KR 20227044517 A KR20227044517 A KR 20227044517A KR 20230003410 A KR20230003410 A KR 20230003410A
- Authority
- KR
- South Korea
- Prior art keywords
- chlorokynurenine
- pain
- dose
- administration
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Lubricants (AREA)
- Quinoline Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020237021428A KR20230098711A (ko) | 2013-01-22 | 2014-01-22 | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361849191P | 2013-01-22 | 2013-01-22 | |
| US61/849,191 | 2013-01-22 | ||
| PCT/US2014/012598 WO2014116739A1 (en) | 2013-01-22 | 2014-01-22 | Dosage forms and therapeutic uses l-4-chlorokynurenine |
| KR1020217039478A KR20210149905A (ko) | 2013-01-22 | 2014-01-22 | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217039478A Division KR20210149905A (ko) | 2013-01-22 | 2014-01-22 | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237021428A Division KR20230098711A (ko) | 2013-01-22 | 2014-01-22 | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230003410A true KR20230003410A (ko) | 2023-01-05 |
Family
ID=51228003
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227044517A Ceased KR20230003410A (ko) | 2013-01-22 | 2014-01-22 | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| KR1020237021428A Ceased KR20230098711A (ko) | 2013-01-22 | 2014-01-22 | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| KR1020217039478A Ceased KR20210149905A (ko) | 2013-01-22 | 2014-01-22 | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| KR1020157022405A Active KR102257284B1 (ko) | 2013-01-22 | 2014-01-22 | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| KR1020217015432A Active KR102335919B1 (ko) | 2013-01-22 | 2014-01-22 | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237021428A Ceased KR20230098711A (ko) | 2013-01-22 | 2014-01-22 | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| KR1020217039478A Ceased KR20210149905A (ko) | 2013-01-22 | 2014-01-22 | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| KR1020157022405A Active KR102257284B1 (ko) | 2013-01-22 | 2014-01-22 | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| KR1020217015432A Active KR102335919B1 (ko) | 2013-01-22 | 2014-01-22 | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
Country Status (22)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3216579A1 (en) | 2013-01-22 | 2014-07-31 | Vistagen Therapeutics, Inc. | Dosage forms and therapeutic uses of l-4-chlorokynurenine |
| DK3297619T3 (da) * | 2015-05-22 | 2022-08-15 | Vistagen Therapeutics Inc | Terapeutiske anvendelser af L-4-chlorkynurenin |
| WO2017044516A1 (en) * | 2015-09-08 | 2017-03-16 | Cephalon, Inc. | Prodrugs of chlorokynurenines |
| CN112236412B (zh) | 2018-02-09 | 2024-01-30 | 维斯塔津治疗公司 | 4-氯代犬尿氨酸及中间体的合成 |
| CN109223785A (zh) * | 2018-10-29 | 2019-01-18 | 中国药科大学 | 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用 |
| WO2022082100A1 (en) * | 2020-10-16 | 2022-04-21 | Vistagen Therapeutics, Inc. | Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| US5360814A (en) | 1991-02-28 | 1994-11-01 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5484814A (en) * | 1991-02-28 | 1996-01-16 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| TW518218B (en) | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| CA2457011C (en) | 2001-08-20 | 2012-04-24 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
| JP2006502158A (ja) | 2002-09-06 | 2006-01-19 | デュレクト コーポレーション | グルタメート媒介神経伝達のモジュレーターの内耳への送達 |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| AU2007235876A1 (en) | 2006-04-12 | 2007-10-18 | Probiodrug Ag | Enzyme inhibitors |
| EP1903028A1 (en) * | 2006-09-22 | 2008-03-26 | Werner Tschollar | Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects |
| CA2606658A1 (en) | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| WO2009135091A1 (en) * | 2008-04-30 | 2009-11-05 | Medivation Technologies, Inc. | Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions |
| CN102159077A (zh) * | 2008-08-21 | 2011-08-17 | 吉瑞工厂 | 用于治疗神经性疼痛的方法 |
| PT2421519T (pt) | 2009-04-23 | 2017-01-26 | Univ Zuerich | Bloqueadores do recetor nmda para o tratamento de anemia falciforme |
| RU2012101424A (ru) * | 2009-06-17 | 2013-07-27 | Таргасепт, Инк. | Устранение l-дофа-индуцированной дискинезии с помощью лигандов нейрональных никотиновых рецепторов |
| JPWO2011019072A1 (ja) | 2009-08-12 | 2013-01-17 | ヒューマン・メタボローム・テクノロジーズ株式会社 | うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体 |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| EP2338873A1 (en) * | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
| AU2011267474B2 (en) * | 2010-06-15 | 2016-05-26 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| CA3216579A1 (en) | 2013-01-22 | 2014-07-31 | Vistagen Therapeutics, Inc. | Dosage forms and therapeutic uses of l-4-chlorokynurenine |
| JP2016513718A (ja) | 2013-03-14 | 2016-05-16 | ヴィスタゲン セラピューティクス、インコーポレイテッド | キラルキヌレニン化合物及び中間体の合成 |
| US9745342B2 (en) | 2013-10-28 | 2017-08-29 | Naurex, Inc. | NMDA receptor modulators and prodrugs, salts, and uses thereof |
| DK3297619T3 (da) | 2015-05-22 | 2022-08-15 | Vistagen Therapeutics Inc | Terapeutiske anvendelser af L-4-chlorkynurenin |
-
2014
- 2014-01-22 CA CA3216579A patent/CA3216579A1/en active Pending
- 2014-01-22 CN CN202110387953.8A patent/CN113209068A/zh active Pending
- 2014-01-22 EP EP17170079.2A patent/EP3228313B1/en active Active
- 2014-01-22 BR BR112015017535-0A patent/BR112015017535A2/pt not_active IP Right Cessation
- 2014-01-22 AU AU2014209466A patent/AU2014209466B2/en active Active
- 2014-01-22 PT PT171700792T patent/PT3228313T/pt unknown
- 2014-01-22 EP EP14743570.5A patent/EP2948140B1/en active Active
- 2014-01-22 HR HRP20240812TT patent/HRP20240812T1/hr unknown
- 2014-01-22 US US14/762,015 patent/US9993450B2/en active Active
- 2014-01-22 CA CA2898619A patent/CA2898619C/en active Active
- 2014-01-22 HU HUE19196366A patent/HUE067381T2/hu unknown
- 2014-01-22 KR KR1020227044517A patent/KR20230003410A/ko not_active Ceased
- 2014-01-22 JP JP2015553921A patent/JP6436913B2/ja active Active
- 2014-01-22 PT PT147435705T patent/PT2948140T/pt unknown
- 2014-01-22 MX MX2015009277A patent/MX375318B/es active IP Right Grant
- 2014-01-22 EP EP24164414.5A patent/EP4385563A3/en not_active Withdrawn
- 2014-01-22 DK DK19196366.9T patent/DK3598971T3/da active
- 2014-01-22 EP EP19196366.9A patent/EP3598971B1/en active Active
- 2014-01-22 CN CN201480010060.XA patent/CN105073108A/zh active Pending
- 2014-01-22 PL PL19196366.9T patent/PL3598971T3/pl unknown
- 2014-01-22 PT PT191963669T patent/PT3598971T/pt unknown
- 2014-01-22 CN CN202110384159.8A patent/CN113116877A/zh active Pending
- 2014-01-22 CA CA3128321A patent/CA3128321C/en active Active
- 2014-01-22 KR KR1020237021428A patent/KR20230098711A/ko not_active Ceased
- 2014-01-22 KR KR1020217039478A patent/KR20210149905A/ko not_active Ceased
- 2014-01-22 HK HK16105132.0A patent/HK1217170A1/zh unknown
- 2014-01-22 SI SI201432078T patent/SI3598971T1/sl unknown
- 2014-01-22 ES ES19196366T patent/ES2980120T3/es active Active
- 2014-01-22 CN CN202110387961.2A patent/CN112933073A/zh active Pending
- 2014-01-22 SI SI201431410T patent/SI3228313T1/sl unknown
- 2014-01-22 PL PL17170079T patent/PL3228313T3/pl unknown
- 2014-01-22 DK DK14743570.5T patent/DK2948140T3/en active
- 2014-01-22 KR KR1020157022405A patent/KR102257284B1/ko active Active
- 2014-01-22 RS RS20191519A patent/RS59687B1/sr unknown
- 2014-01-22 WO PCT/US2014/012598 patent/WO2014116739A1/en not_active Ceased
- 2014-01-22 KR KR1020217015432A patent/KR102335919B1/ko active Active
- 2014-01-22 DK DK17170079T patent/DK3228313T3/da active
- 2014-01-22 ES ES17170079T patent/ES2751138T3/es active Active
- 2014-01-22 ES ES14743570.5T patent/ES2635353T3/es active Active
-
2015
- 2015-07-17 MX MX2020009966A patent/MX2020009966A/es unknown
- 2015-07-22 IL IL240090A patent/IL240090B/en active IP Right Grant
- 2015-08-03 ZA ZA2015/05569A patent/ZA201505569B/en unknown
-
2016
- 2016-02-08 US US15/018,219 patent/US9993453B2/en active Active
- 2016-11-02 ZA ZA2016/07581A patent/ZA201607581B/en unknown
-
2018
- 2018-05-14 US US15/978,855 patent/US10632091B2/en active Active
- 2018-06-08 US US16/003,793 patent/US10617663B2/en active Active
- 2018-06-08 US US16/003,816 patent/US10980758B2/en active Active
- 2018-06-08 US US16/003,804 patent/US20180369180A1/en not_active Abandoned
- 2018-09-13 JP JP2018171786A patent/JP6804497B2/ja active Active
- 2018-10-26 AU AU2018253600A patent/AU2018253600B2/en active Active
-
2019
- 2019-11-27 CY CY20191101244T patent/CY1122403T1/el unknown
- 2019-12-04 HR HRP20192189TT patent/HRP20192189T1/hr unknown
-
2020
- 2020-07-01 AU AU2020204420A patent/AU2020204420A1/en not_active Abandoned
- 2020-07-03 JP JP2020115273A patent/JP7021298B2/ja active Active
- 2020-07-16 IL IL276126A patent/IL276126B/en unknown
-
2022
- 2022-02-03 JP JP2022015622A patent/JP2022070894A/ja active Pending
- 2022-03-30 IL IL291831A patent/IL291831B2/en unknown
- 2022-06-21 US US17/845,105 patent/US12036198B2/en active Active
- 2022-08-22 AU AU2022221382A patent/AU2022221382B2/en active Active
-
2024
- 2024-02-27 JP JP2024027330A patent/JP2024069257A/ja active Pending
- 2024-03-21 US US18/611,908 patent/US20250161251A1/en active Pending
- 2024-12-18 AU AU2024278564A patent/AU2024278564A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12036198B2 (en) | Dosage forms and therapeutic uses of L-4-chlorokynurenine | |
| HK40022228B (en) | Dosage forms and therapeutic uses l-4- chlorokynurenine | |
| HK40022228A (en) | Dosage forms and therapeutic uses l-4- chlorokynurenine | |
| NZ710121B2 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20221219 Application number text: 1020217039478 Filing date: 20211201 |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230223 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20230703 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20230223 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |